Teleflex to close Minnesota facility, cut 101 employees
Teleflex will close a manufacturing facility in Maple Grove, Minnesota, by next March and cut more than 100 employees as a result.
The planned closure will affect an expected 101 positions, according to a Tuesday Worker Adjustment and Retraining Notification filing obtained by MedTech Dive. The Minnesota Star Tribune first reported the cuts.
Most laboratory and manufacturing operations are expected to cease by June 30, with the layoffs occurring on July 1, according to the filing. Teleflex did not respond to a request for comment on why it was closing the Maple Grove facility.
In February, Teleflex announced it would split into two separate, public entities. A new company would comprise Teleflex's urology, acute care and OEM businesses, while the remaining company would include the vascular access, interventional and surgical businesses. Simultaneously, Teleflex bought Biotronik's vascular intervention division.
Teleflex aims to streamline manufacturing during the restructuring. The company aims to reduce the number of facilities from the combination of Biotronik and the remaining company from 19 facilities to seven, CEO Liam Kelly told investors in February.
The Maple Grove site was used to make diagnostic and interventional catheters, according to the company's website. Teleflex's remaining company had pro forma revenue of $2.1 billion in 2024 with the Biotronik acquisition.
Recommended Reading
Teleflex to split in 2, buy Biotronik assets for $791M among slew of actions
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Abbott lowers sales forecast on diagnostics decline, US funding cuts
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $11.14 billion 7.4% increase year over year Medical device sales: $5.37 billion 13.4% increase year over year Diagnostics sales: $2.17 billion 1% decrease year over year Abbott lowered its sales forecast for the year, citing a drop in diagnostic testing. CEO Robert Ford told investors on Thursday that the company is seeing a drop-off in COVID-19 testing sales, challenges in China's core laboratory market and a reduction in U.S. foreign aid funding for HIV testing, with a combined impact of more than $1 billion. The company reduced its 2025 organic sales growth forecast to a range of 6% to 7%, from the previous forecast of 7.5% to 8.5% shared in the first quarter. 'Even with that billion dollars, we're still forecasting high single-digit growth and absorbing the impact of tariffs,' Ford said. The company now expects 'just under $200 million' of impact from tariffs. CFO Phil Boudreau said the amount was down from previous estimates, when the company had outlined 'a few hundred million' in tariff costs. Discussing how the company plans to mitigate tariffs, Ford said that Abbott plans to open a new cardiovascular manufacturing facility in Georgia in 2028. 'Once tariffs get set in place, they're very difficult to walk away from,' the CEO said, 'so we have to think medium term, but also long term.' Growth in medical devices, diabetes A bright spot for Abbott was its medical device segment, which grew by more than 13% to $5.37 billion in sales. The company's diabetes segment grew by more than 20% to $1.98 billion. Analysts asked about Abbott's plans for a dual analyte sensor that would provide glucose and ketone readings. The company recently showcased the device during the American Diabetes Association's Scientific Sessions. Ford declined to provide a timeline or pricing details for the planned device. BTIG analyst Marie Thibault wrote in June that Abbott's management expects a launch sometime next year. The company is also partnering with insulin pump companies, including Tandem, Sequel Med Tech and Beta Bionics, to support the new sensor. 'I think this is going to be a real next-level, significant change in the CGM market,' Ford said, specifically for intensive insulin users. Abbott's electrophysiology business, with the company's new Volt pulsed field ablation device to treat cardiac arrhythmias, grew by 11.5% to $700 million. Recommended Reading 'We are not rolling over': J&J electrophysiology unit rebounds amid PFA rivalry Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Yahoo
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Contacts: Teleflex Incorporated: Lawrence Keusch Vice President, Investor Relations and Strategy Development
Yahoo
16-07-2025
- Yahoo
Zimmer bets on autonomous surgery with Monogram purchase
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet hopes to round out its surgical robotics portfolio with its planned $177 million purchase of Monogram Technologies, which was announced Monday. The acquisition could offer more customer choice, analysts wrote, but they also questioned whether surgeons will prefer an autonomous robot. Monogram received Food and Drug Administration clearance in March for a semi-autonomous, AI-navigated robot called mBôs, to be used in total knee replacement surgeries. The company plans to launch mBôs with Zimmer's Persona knee implants in early 2027, according to an investor presentation. Monogram is working on a fully autonomous version of the robot, which would be hands-free and activated using foot pedals, that it plans to launch in late 2027 or early 2028. Zimmer already has a robot that can be used for total knee replacements, called Rosa, but that system currently does not work with CT imaging and uses manual cutting. After closing, Zimmer expects to have 'the most comprehensive suite of customer-centric technology solutions, ranging from simplified navigation, such as OrthoGrid, to non-CT based robotics with Rosa, and fully autonomous robots with mBôs,' according to the investor presentation. Analysts said the deal is designed to give surgeons more options, but also raised questions about the acquisition. Mike Matson, an analyst with Needham, said buying Monogram may 'improve and differentiate' Zimmer's robotics, but questioned the level of surgeon interest in a fully automated robotics system, in a research note published Monday. BTIG analyst Ryan Zimmerman wrote in a research note that the price was high for a robotics system that has not sold any units yet, and asked what the deal means for Rosa, given the updates planned for the coming quarters. 'This is about customer choice, defining the fully autonomous category of robotics, and appealing to surgeons who prefer autonomous cutting over manual cutting (which is ROSA today),' Zimmerman wrote, citing a conversation with the orthopedic firm's management. Shagun Singh, an analyst with RBC Capital Markets, wrote that Zimmer plans to grow its business by gaining more share in the robotic market, increasing how many procedures are done using robotics, driving more revenue per procedure, and expanding the market by creating a new category of fully autonomous robots. More acquisitions likely to come Zimmer also used the announcement to outline future plans for its robotics program. The company's Rosa robots are 'rapidly approaching 2,000 installations worldwide' and are a market leader outside of the U.S., Zimmer said in a press release. Zimmer received FDA clearance last year to use Rosa for robot-assisted shoulder replacements, and plans a full launch of the feature in early 2026. The company is working on a posterior hip feature for Rosa for the second half of 2026, and a CT imaging feature for early 2027, according to the investor presentation. Last year, Zimmer bought OrthoGrid Systems, which makes AI guidance systems for total hip replacement surgeries. It also struck a distribution agreement with Think Surgical, which makes a CT-enabled, handheld robot. 'Management explained that these technologies are not competitive, but allow a more complimentary suite,' Singh wrote. In April, Zimmer bought Paragon 28, an orthopedics company focused on foot and ankle procedures, for $1.1 billion. Analysts see Zimmer as poised to continue its streak of acquisitions. Needham's Matson wrote that 'despite the recent acquisition of Paragon 28 and today's announcement, we still think that [Zimmer] may pursue additional acquisitions in higher-growth orthopedic subcategories like data/AI, enabling technologies, sports medicine, and extremities.' Recommended Reading Zimmer to buy robotics firm Monogram for about $177M Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
